Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its 2020 Q1 net loss rose about 97 percent year over year, as it reached the cusp of recognizing its first ever revenues.

The liquid biopsy firm's net loss for the three months ended March 31 was $7.7 million, or $0.13 per share, compared to $3.9 million, or $.08 per share, in the same quarter last year, exceeding the consensus Wall Street estimate of a loss of $0.11 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.